MBX Biosciences

Metabolic Trailblazers Bring Precision to Endocrine Disorders

Maintaining Optimal Levels of PTH: With Phase 2 trial design and rationale established, MBX-2109 has demonstrated ability in Phase 1 for once-weekly dosing to deliver consistent and optimal parathyroid hormone (PTH) levels. This offers significant promise for patients with hypoparathyroidism (HP) who must account for low PTH by constantly taking supplements to maintain blood calcium levels
Platform for Precision: Based on technology from the lab of peptide pioneer Richard DiMarchi, Ph.D., MBX is overcoming a key limitation of peptides as medicine – short half-life that mandates repeat dosing and variability in blood concentrations – with treatments designed to have sustained effect in patients for better convenience and outcomes
The Obesity Race: MBX 4291 is a long-acting GLP-1/GIP Receptor co-agonist, in development as a potential treatment for obesity. This preclinical therapy has the potential for improved GI tolerability, less frequent administration and reduced dosing complexity.
Key Events in 2025: Following the closing of an upsized IPO in September of 2024, MBX has key upcoming milestones in 2025 including topline study results for the Phase 2 MBX-2109 trial in patients with HP expected in Q3 2025. MBX is also advancing a second program, MBX-1416, for potential treatment of post-bariatric hypoglycemia in its Phase 1/2 clinical trial